The role of neoadjuvant chemotherapy versus primary surgery in the management of stage III ovarian cancer

Peritoneal Carcinomatosis: A Multidisciplinary Approach

Volumn , Issue , 2007, Pages 387-402

  Van Gorp, Toon ^a   Amant, Frederic ^a   Neven, Patrick ^a   Berteloot, Patrick ^a   Leunen, Karin ^a   Vergote, Ignace ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT THERAPY; CANCER STAGING; COMPARATIVE STUDY; FEMALE; HUMAN; LAPAROSCOPY; MINIMALLY INVASIVE SURGERY; OVARY TUMOR; PATHOLOGY; REVIEW;

FEMALE; HUMANS; LAPAROSCOPY; NEOADJUVANT THERAPY; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURGICAL PROCEDURES, MINIMALLY INVASIVE;

EID: 84892833403     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-48993-3_25     Document Type: Chapter

References (67)

1. Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore M, Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck HJ, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MKB, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJS, Sessa C, Thigpen JT, Trope C, Tuxen MK, Vergote I, Vermorken JB, Willemse PHB (1999) Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol 10: 87-92
2. Meigs JV (1934) Tumors of the pelvic organs. Macmillan: New York, NY
3. Hudson CN (1968) A radical operation for fixed ovarian tumours. J Obstet Gynaecol Br Commonw 75: 1155-1160
4. Aure JC, Hoeg K, Kolstad P (1971) Clinical and histologic studies of ovarian carcinoma. Long-term follow-up of 990 cases. Obstet Gynecol 37: 1-9
5. Griffiths CT, Fuller AF (1978) Intensive Surgical and Chemotherapeutic Management of Advanced Ovarian Cancer. Surg Clin North Am 58: 131-142
6. Berek JS, Trope C, Vergote I (1999) Surgery during chemotherapy and at relapse of ovarian cancer. Ann Oncol 10: 3-7
7. Skipper HE (1974) Thoughts on Cancer Chemotherapy and Combination Modality Therapy (1974). Jama-Journal of the American Medical Association 230: 1033-1035
8. Goldie JH, Coldman AJ (1979) Mathematic Model for Relating the Drug Sensitivity of Tumors to Their Spontaneous Mutation-Rate. Cancer Treat Rep 63: 1727-1733
9. Smith JP, Day TG (1979) Review of Ovarian-Cancer at the University-Of- Texas-Systems-Cancer-Center, Md-Anderson-Hospital-And-Tumor-Institute. Am J Obstet Gynecol 135: 984-993
10. Bertelsen K, Jakobsen A, Andersen JE, Ahrons S, Pedersen PH, Kiaer H, Arffmann E, Bichel P, Boestofte E, Christophersen IS, Gregersen E, Hansen MK, Holund B, Jacobsen M, Jensen HK, Jepsen FL, Larsen G, Nielsen ES, Nyland M, Olsen J, Panduro J, Rank F, Sell A, Sogaard H (1987) A Randomized Study of Cyclophosphamide and Cisplatinum with Or Without Doxorubicin in Advanced Ovarian-Carcinoma. Gynecol Oncol 28: 161-169
11. Marsoni S (1987) Randomized Comparison of Cisplatin with Cyclophosphamide Cisplatin and with Cyclophosphamide Doxorubicin Cisplatin in Advanced Ovarian-Cancer. Lancet 2: 353-359
12. Voest EE, Vanhouwelingen JC, Neijt JP (1989) A Meta-Analysis of Prognostic Factors in Advanced Ovarian-Cancer with Median Survival and Overall Survival (Measured with the Log (Relative Risk)) As Main Objectives. Eur J Cancer Clin Oncol 25: 711-720
13. Hunter RW, Alexander NDE, Soutter WP (1992) Metaanalysis of Surgery in Advanced Ovarian-Carcinoma - Is Maximum Cytoreductive Surgery An Independent Determinant of Prognosis. Am J Obstet Gynecol 166: 504-511
14. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: A meta-analysis. J Clin Oncol 20: 1248-1259
15. Heintz APM, Hacker NF, Berek JS, Rose TP, Munoz AK, Lagasse LD (1986) Cytoreductive Surgery in Ovarian-Carcinoma - Feasibility and Morbidity. Obstet Gynecol 67: 783-788
16. Potter ME, Partridge EE, Hatch KD, Soong SJ, Austin JM, Shingleton HM (1991) Primary Surgical Therapy of Ovarian-Cancer - How Much and When. Gynecol Oncol 40: 195-200
17. Redman JR, Petroni GR, Saigo PE, Geller NL, Hakes TB (1986) Prognostic Factors in Advanced Ovarian-Carcinoma. J Clin Oncol 4: 515-523
18. Neijt JP, Tenbokkelhuinink WW, Vanderburg MEL, Vanoosterom AT, Wil-lemse PHB, Heintz APM, Vanlent M, Trimbos JB, Bouma J, Vermorken JB, Vanhouwelingen JC (1987) Randomized Trial Comparing 2 Combination Chemotherapy Regimens (CHAP-5 v CP) in Advanced Ovarian-Carcinoma. J Clin Oncol 5: 1157-1168
19. Hacker NF, Berek JS, Lagasse LD, Nieberg RK, Elashoff RM (1983) Primary Cytoreductive Surgery for Epithelial Ovarian-Cancer. Obstet Gynecol 61: 413-420
20. Heintz APM, Vanoosterom AT, Baptist J, Trimbos MC, Schaberg A, Van-dervelde EA, Nooy M (1988) The Treatment of Advanced Ovarian-Carcinoma. 1. Clinical-Variables Associated with Prognosis. Gynecol Oncol 30: 347-358
21. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA (1992) The Influence of Cy-toreductive Surgery on Recurrence-Free Interval and Survival in Small-Volume Stage-III Epithelial Ovarian-Cancer - A Gynecologic Oncology Group-Study. Gynecol Oncol 47: 159-166
22. Vergote I, De Wever I, Tjalma W, Van Gramberen M, Decloedt J, van Dam P (1998) Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: A retrospective analysis of 285 patients. Gynecol Oncol 71: 431-436
23. Eisenkop SM, Spirtos NM (2001) What are the current surgical objectives, strategies, and technical capabilities of gynecologic oncologists treating advanced epithelial ovarian cancer? Gynecol Oncol 82: 489-497
24. Burghardt E, Girardi F, Lahousen M, Tamussino K, Stettner H (1991) Patterns of Pelvic and Paraaortic Lymph-Node Involvement in Ovarian-Cancer. Gynecol Oncol 40: 103-106
25. Friedlander ML, Hedley DW, Swanson C, Russell P (1988) Prediction of Long-Term Survival by Flow Cytometric Analysis of Cellular Dna Content in Patients with Advanced Ovarian-Cancer. J Clin Oncol 6: 282-290
26. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR (2004) Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190: 910-922
27. Kehoe S, Powell J, Wilson S, Woodman C (1994) The Influence of the Operating Surgeons Specialization on Patient Survival in Ovarian-Carcinoma. Br J Cancer 70: 1014-1017
28. Wright JD, Herzog TJ, Powell MA (2004) Morbidity of cytoreductive surgery in the elderly. Am J Obstet Gynecol 190: 1398-1400
29. Farias-Eisner R, Teng F, Oliveira M, Leuchter R, Karlan B, Lagasse LD, Berek JS (1994) The influence of tumor grade, distribution, and extent of car-cinomatosis in minimal residual stage III epithelial ovarian cancer after optimal primary cytoreductive surgery. Gynecol Oncol 55: 108-110
30. Eisenkop SM, Nalick RH, Wang HJ, Teng NNH (1993) Peritoneal Implant Elimination During Cytoreductive Surgery for Ovarian-Cancer - Impact on Survival. Gynecol Oncol 51: 224-229
31. vanDam PA, Tjalma W, Weyler J, Vanoosterom AT, Buytaert P (1996) Ultra-radical debulking of epithelial ovarian cancer with the ultrasonic surgical aspirator: A prospective randomized trial. Am J Obstet Gynecol 174: 943-950
32. Naik R, Nordin A, Cross PA, Hemming D, Lopes AD, Monaghan JM (2000) Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases. Gynecol Oncol 78: 171-175
33. Akahira J-I, Yoshikawa H, Shimizu Y, Tsunematsu R, Hirakawa T, Kuramoto H, Shiromizu K, Kuzuya K, Kamura T, Kikuchi Y (2001) Prognostic Factors of Stage IV Epithelial Ovarian Cancer: A Multicenter Retrospective Study. Gynecol Oncol 81: 398-403
34. Zang RY, Zhang ZY, Cai SM, Li ZT, Chen J, Tang MQ, Liu Q (1999) Cytoreductive surgery for stage IV epithelial ovarian cancer. J Exp Clin Cancer Res 18: 449-454
35. van der Burg ME, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G, Lacave AJ, Nardi M, Renard J, Pecorelli S (1995) The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med 332: 629-634
36. Rose PG, Nerenstone S, Brady MF, et al (2002) A phase III randomised study of interval secondary cytoreducion in patients with advanced stage ovarian carcinoma with suboptimal residual disease: a Gynecologic Oncology Group study. Proceedings of ASCO 21: 201a
37. Donadio M, Bonardi G, Iberti V, Bertetto O, Carnino F, Iskra L, Mossetti C, Calciati A (1989) The role of induction chemotherapy in inoperable ovarian cancer. Tumori 75: 609-614
38. Lawton FG, Redman CWE, Luesley DM, Chan KK, Blackledge G (1989) Neoadjuvant (Cytoreductive) Chemotherapy Combined with Intervention De-bulking Surgery in Advanced, Unresected Epithelial Ovarian-Cancer. Obstet Gynecol 73: 61-65
39. Tummarello D, Menichetti ET, Miseria S, Torresi U, Guidi F, Gramazio A, Vissani L, Cellerino R (1990) Advanced epithelial ovarian cancer: no difference in survival rate between exploratory laparotomy and inadequate debulk-ing surgery as treatment approach before chemotherapy. J Chemother 2: 260-263
40. Jacob JH, Gershenson DM, Morris M, Copeland LJ, Burke TW, Wharton JT (1991) Neoadjuvant Chemotherapy and Interval Debulking for Advanced Epithelial Ovarian-Cancer. Gynecol Oncol 42: 146-150
41. Lim JT, Green JA (1993) Neoadjuvant carboplatin and ifosfamide chemotherapy for inoperable FIGO stage III and IV ovarian carcinoma. Clin Oncol (R Coll Radiol) 5: 198-202
42. Shimizu Y, Hasumi K (1993) [Treatment of stage III and IV ovarian cancer-is neoadjuvant chemotherapy effective?]. Nippon Sanka Fujinka Gakkai Zasshi 45: 1007-1014
43. Onnis A, Marchetti M, Padovan P, Castellan L (1996) Neoadjuvant chemotherapy in advanced ovarian cancer. Eur J Gynaecol Oncol 17: 393-396
44. Surwit E, Childers J, Atlas I, Nour M, Hatch K, Hallum A, Alberts D (1996) Neoadjuvant chemotherapy for advanced ovarian cancer. Int J Gynecol Cancer 6: 356-361
45. Schwartz PE, Rutherford TJ, Chambers JT, Kohorn EI, Thiel RP (1999) Neoadjuvant chemotherapy for advanced ovarian cancer: Long-term survival. Gynecol Oncol 72: 93-99
46. Ansquer Y, Leblanc E, Clough K, Morice P, Dauplat J, Mathevet P, Lhomme C, Scherer C, Tigaud JD, Benchaib M, Fourme E, Castaigne D, Querleu D, Dargent D (2001) Neoadjuvant chemotherapy for unresectable ovarian carcinoma - A French multicenter study. Cancer 91: 2329-2334
47. Kuhn W, Rutke S, Spathe K, Schmalfeldt B, Florack G, von Hundelshausen B, Pachyn D, Ulm K, Graeff H (2001) Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. Cancer 92: 2585-2591
48. Recchia F, De Filippis S, Rosselli M, Saggio G, Carta G, Rea S (2001) Primary chemotherapy in stage IV ovarian cancer. A prospective phase II study. Eur J Gynaecol Oncol 22: 287-291
49. Kayikcioglu F, Kose MF, Boran N, Caliskan E, Tulunay G (2001) Neoadju-vant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma. Int J Gynecol Cancer 11: 466-470
50. Ushijima K, Ota S, Komai K, Matsuo G, Motoshima S, Honda S, Tomonari R, Sugiyama T, Kamura T (2002) Clinical assessment of neoadjuvant chemotherapy and interval cytoreductive surgery for unresectable advanced ovarian cancer. Int Surg 87: 185-190
51. Fanfani F, Ferrandina G, Corrado G, Fagotti A, Zakut HV, Mancuso S, Scambia G (2003) Impact of interval debulking surgery on clinical outcome in primary unresectable FIGO stage IIIc ovarian cancer patients. Oncology 65: 316-322
52. Shibata K, Kikkawa F, Mika M, Suzuki Y, Kajiyama H, Ino K, Mizutani S (2003) Neoadjuvant chemotherapy for FIGO stage III or IV ovarian cancer: Survival benefit and prognostic factors. Int J Gynecol Cancer 13: 587-592
53. Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhomme C, Pautier P, Pomel C, Camatte S, Duvillard P, Castaigne D (2003) Results of interval debulking surgery in advanced stage ovarian cancer: an exposed-non-exposed study. Ann Oncol 14: 74-77
54. Morice P, Dubernard G, Rey A, Atallah D, Pautier P, Pomel C, Lhomme C, Duvillard P, Castaigne D (2003) Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer. J Am Coll Surg 197: 955-963
55. Mazzeo F, Berliere M, Kerger J, Squifflet J, Duck L, D'Hondt V, Humblet Y, Donnez J, Machiels JP (2003) Neoadjuvant chemotherapy followed by surgery and adjuvant chemotherapy in patients with primarily unresectable, advanced-stage ovarian cancer. Gynecol Oncol 90: 163-169
56. Chan YM, Ng TY, Ngan HY, Wong LC (2003) Quality of life in women treated with neoadjuvant chemotherapy for advanced ovarian cancer: a prospective longitudinal study. Gynecol Oncol 88: 9-16
57. Le T, Faught W, Hopkins L, Fung Kee FM (2005) Primary chemotherapy and adjuvant tumor debulking in the management of advanced-stage epithelial ovarian cancer. Int J Gynecol Cancer 15: 770-775
58. Hegazy MA, Hegazi RA, Elshafei MA, Setit AE, Elshamy MR, Eltatoongy M, Halim AA (2005) Neoadjuvant chemotherapy versus primary surgery in advanced ovarian carcinoma. World J Surg Oncol 3: 57
59. Loizzi V, Cormio G, Resta L, Rossi CA, DI Gilio AR, Cuccovillo A, Selvaggi L (2005) Neoadjuvant chemotherapy in advanced ovarian cancer: a case-control study. Int J Gynecol Cancer 15: 217-223
60. Lee SJ, Kim BG, Lee JW, Park CS, Lee JH, Bae DS (2006) Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery. J Obstet Gynaecol Res 32: 99-106
61. Bristow RE, Chi DS (2006) Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: A meta-analysis. Gynecol Oncol
62. Nelson BE, Rosenfield AT, Schwartz PE (1993) Preoperative Abdominopel-vic Computed Tomographic Prediction of Optimal Cytoreduction in Epithelial Ovarian-Carcinoma. J Clin Oncol 11: 166-172
63. Bristow RE, Duska LR, Lambrou NC, Fishman EK, O'Neill MJ, Trimble EL, Montz FJ (2000) A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography. Cancer 89: 1532-1540
64. Tate S, Hirai Y, Takeshima N, Hasumi K (2005) CA125 regression during neoadjuvant chemotherapy as an independent prognostic factor for survival in patients with advanced ovarian serous adenocarcinoma. Gynecol Oncol 96: 143-149
65. Berchuck A, Iversen ES, Lancaster JM, Dressman HK, West M, Nevins JR, Marks JR (2004) Prediction of optimal versus suboptimal cytoreduction of advanced-stage serous ovarian cancer with the use of microarrays. Am J Obstet Gynecol 190: 910-925
66. Gryspeerdt S, Clabout L, Van Hoe L, Berteloot P, Vergote IB (1998) Intrap-eritoneal contrast material combined with CT for detection of peritoneal me-tastases of ovarian cancer. Eur J Gynaecol Oncol 19: 434-437
67. Vergote I, Marquette S, Amant F, Berteloot P, Neven P (2005) Port-site me-tastases after open laparoscopy: a study in 173 patients with advanced ovarian carcinoma. Int J Gynecol Cancer 15: 776-779